Trichomegaly following treatment with gefitinib (ZD1839)

Pascual, José C.; Bañuls, José; Belinchón, I.; Blanes, Mar; Massutí, Bartomeu

doi:10.1111/j.1365-2133.2004.06265.x

Cited by 72 publications

(45 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This condition was initially identified in patients with certain congenital syndromes, including the Oliver-McFarlane syndrome (8), Cornelia de Lange syndrome (9) or familial hypertrichosis (10). Acquired trichomegaly is also associated with specific drugs (11,12) and other diseases, including vernal keratoconjunctivitis and atopic dermatitis (13,14). However, eyelash trichomegaly is not a drug-limiting side effect.…”

Section: Discussionmentioning

confidence: 99%

Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review

et al. 2015

View full text Add to dashboard Cite

Abstract. Inhibitors of epidermal growth factor receptor (EGFR), including tyrosine kinase inhibitors (TKIs), present significant clinical benefits in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with an EGFR mutation. However, TKI treatment also results in unwanted cutaneous toxic side effects, such as a skin rash. Eyelash trichomegaly is rarely reported as a side effect; however, it causes cosmetic issues or eyeball irritation in patients, which may result in the early termination of TKI treatment. Therefore, although TKI-induced eyelash trichomegaly is rare, it should be considered carefully by lung cancer physicians. The present study reported a case of erlotinib-induced eyelash trichomegaly in a 65-year-old Chinese female patient suffering from NSCLC with an EGFR mutation. To the best of our knowledge, this is the first reported case of erlotinib-induced trichomegaly in a Chinese patient.

show abstract

Section: Discussionmentioning

confidence: 99%

Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[9][10][11][12] 1.3. Ungueal, subungueal, and periungueal alterations Nail alterations can present with a reduction of the nail growth speed, fragility, lines of discoloration (Mees' lines), transversal depressions (Beau's lines), hyperpigmentation, onycholysis with subungueal aseptic abcesses, photoonycholysis, paronychia, and pyogenic granulomas of the periungueal folds.…”

Section: Trichomegaly and Hair Curlingmentioning

confidence: 99%

Reações tegumentares adversas relacionadas aos agentes antineoplásicos: parte I

Sanches

Brandt

Moure

et al. 2010

An. Bras. Dermatol.

View full text Add to dashboard Cite

Abstract:The local and systemic treatment of tumors can cause changes in the skin, mucous membranes, hair and nails. Accurate diagnosis and appropriate treatment of side effects require knowledge about the patterns of the most common adverse reactions to drugs the patient may be using. The dermatologist must be familiar with the manifestations of certain soft tissue neoplasms, as well as with the adverse mucocutaneous forms of cancer treatment. Keyword s: Chemotherapy, adjuvant; Drug therapy; Drug therapy, combination; Skin; Skin abnormalities; Skin pigmentation Resumo: O tratamento local e sistêmico das neoplasias pode causar alterações na pele, membranas mucosas, cabelos e unhas. O diagnóstico preciso e o tratamento adequado destes efeitos colaterais requerem conhecimento dos padrões das reações adversas mais comuns para as medicações que o paciente está utilizando. O dermatologista deve estar familiarizado com as manifestações tegumentares das neoplasias, bem como com os efeitos adversos mucocutâneos dos tratamentos antineoplásicos.

show abstract

“…Elles se localisent au dé but sur les ré gions sé borrhé iques riches en glandes pilosé bacé es, touchant le « T » facial (front, sillon nasolabial, menton) ainsi que le cou, le dé colleté et le haut du dos, pouvant s'é tendre secondairement. Dans les formes plus graves, profuses, le reste du té gument peut ê tre atteint (membres, abdomen, ré gion lombaire, fesses, organes gé nitaux externes) [11,12,15,18]. Cette atteinte se distingue de l'acné vulgaire, tout comme les autres acné s mé dicamenteuses par son caractè re monomorphe, papuleux et pustuleux.…”

Section: Mots Clé S : Anti-egf-r -Rash Cutané -Paronychie -Trichomé -unclassified

“…L'é ruption cutané e é tait de mê me nature pour les deux types de molé cules, avec toutefois la pré sence de lé sions plus é tendues et de croû tes hé morragiques plus prononcées dans le groupe traité par cetuximab. Pascual et al ont rapporté le dé cè s d'un patient traité par gefitinib suite à une é rythrodermie desquamative [15]. L'imputabilité n'a toutefois pas pu ê tre retenue de faç on formelle.…”

Section: Mots Clé S : Anti-egf-r -Rash Cutané -Paronychie -Trichomé -unclassified